Please use this identifier to cite or link to this item: http://scholarbank.nus.edu.sg/handle/10635/120520
Title: CHARACTERIZATION OF NEUTRALIZING ANTIBODIES AGAINST CHIKUNGUNYA VIRUS REPLICATION
Authors: SHIRLEY LAM
Keywords: Chikungunya virus, IgM, Neutralizing, replication, antibodies
Issue Date: 11-May-2015
Citation: SHIRLEY LAM (2015-05-11). CHARACTERIZATION OF NEUTRALIZING ANTIBODIES AGAINST CHIKUNGUNYA VIRUS REPLICATION. ScholarBank@NUS Repository.
Abstract: CHIKUNGUNYA VIRUS (CHIKV) IS A MEDICALLY IMPORTANT HUMAN VIRAL PATHOGEN THAT CAUSES CHIKUNGUNYA FEVER ACCOMPANIED WITH DEBILITATING JOINT PAIN. HOST-ELICITED OR PASSIVELY-TRANSFERRED MONOCLONAL ANTIBODIES (MAB) ARE ESSENTIAL MEDIATORS OF CHIKV CLEARANCE. THEREFORE, THIS STUDY AIMS TO CHARACTERIZE A PANEL OF MABS FOR THEIR NEUTRALIZATION EFFICACY AGAINST CHIKV INFECTION IN A CELL-BASED AND MURINE MODEL. BOTH IGM 3E7B AND 8A2C BIND STRONGLY TO NATIVE CHIKV SURFACE AND POTENTLY NEUTRALIZES CHIKV REPLICATION. FURTHER ANALYSES ON CHIKV SINGLE MUTANT CLONES REVEALED THAT N218 OF CHIKV E2 PROTEIN IS A POTENT NEUTRALIZING EPITOPE. IN ADDITION, 3E7B BLOCKS CHIKV ATTACHMENT TO PERMISSIVE CELLS, POSSIBLY BY BINDING TO THE SURFACE-ACCESSIBLE E2-N218 RESIDUE. PROPHYLACTIC ADMINISTRATION OF 3E7B TO NEONATE MICE MARKEDLY REDUCED VIREMIA AND PROTECTED AGAINST CHIKV. GIVEN AT 4 H POST-INFECTION, 3E7B CONFERRED 100% SURVIVAL RATE AND SIMILARLY REDUCED CHIKV LOAD IN MOST MICE TISSUES EXCEPT THE LIMB MU
URI: http://scholarbank.nus.edu.sg/handle/10635/120520
Appears in Collections:Master's Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
LamS.MSC THESIS_FINAL E-version(1).pdf20.06 MBAdobe PDF

OPEN

NoneView/Download
LamS.MSC THESIS_FINAL E-version(2).pdf14.45 MBAdobe PDF

OPEN

NoneView/Download
LamS.MSC THESIS_FINAL E-version(3).pdf27.25 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

131
checked on Oct 12, 2018

Download(s)

20
checked on Oct 12, 2018

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.